Edesa Biotech, Inc. (EDSA)
NASDAQ: EDSA · Real-Time Price · USD
5.30
-0.22 (-3.99%)
At close: Aug 12, 2026, 4:00 PM EDT
5.20
-0.10 (-1.88%)
After-hours: Aug 12, 2026, 7:50 PM EDT
Edesa Biotech Revenue
Edesa Biotech had revenue of $107.80K in the twelve months ending March 31, 2026.
Revenue (ttm)
$107.80K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
51.06M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | 328.80K | - | - |
| Dec 31, 2018 | - | - | - |
| Sep 30, 2018 | 211.85K | - | - |
| Dec 31, 2017 | - | - | - |
| Sep 30, 2017 | 228.29K | -1.04M | -82.05% |
| Sep 30, 2016 | 1.27M | 513.00K | 67.62% |
| Sep 30, 2015 | 758.69K | 705.90K | 1,337.29% |
| Sep 30, 2014 | 52.79K | -319.35K | -85.82% |
| Aug 31, 2014 | 372.13K | 358.29K | 2,589.01% |
| Sep 30, 2013 | 13.84K | -531.63K | -97.46% |
| Aug 31, 2013 | 545.47K | 259.42K | 90.69% |
| Aug 31, 2012 | 286.05K | -411.13K | -58.97% |
| Aug 31, 2011 | 697.19K | -157.65K | -18.44% |
| Aug 31, 2010 | 854.84K | -54.91K | -6.04% |
| Aug 31, 2009 | 909.75K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| TScan Therapeutics | 7.11M |
| Immutep | 5.28M |
| Alps Group | 3.74M |
| RenovoRx | 1.49M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| INmune Bio | 50.00K |
EDSA News
- 5 weeks ago - Edesa Biotech files to sell 729,241 common shares for holders - TheFly
- 6 weeks ago - Edesa Biotech reinstated with a Buy at Brookline - TheFly
- 2 months ago - Edesa Biotech announces $3.5M private placement - TheFly
- 2 months ago - Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors - GlobeNewsWire
- 2 months ago - Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury - GlobeNewsWire
- 3 months ago - Edesa Biotech Inc trading resumes - TheFly
- 3 months ago - Edesa Biotech Inc trading halted, volatility trading pause - TheFly
- 3 months ago - Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference - GlobeNewsWire